Want to see TSE:DOSE full AI Analyst Report?
DOSE Stock Chart & Stats
C$0.09
<C$0.01(5.56%)
At close: 4:00 PM EDT
C$0.09
<C$0.01(5.56%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.20
Previous CloseN/A
Volume11.00K
Average Volume (3M)36.09K
Market Cap
C$13.64M
Enterprise ValueC$20.79
Total Cash (Recent Filing)C$14.65K
Total Debt (Recent Filing)C$5.81M
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding136,444,840
10 Day Avg. Volume35,351
30 Day Avg. Volume36,089
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-2.78
Price to Sales (P/S)7.19
P/FCF Ratio-73.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Oral Thin‑film Drug‑delivery PlatformA proprietary oral thin‑film delivery platform provides a durable strategic asset: it addresses multiple therapeutic and consumer‑health use cases, supports licensing or contract‑manufacturing models, and can create structural differentiation versus traditional pills over the medium term.
Positive Recent Operating Cash FlowTrailing‑12M operating and free cash flow turned positive (~$0.17M), representing a meaningful operational improvement versus prior negative periods. This improved cash generation, although small, reduces immediate liquidity pressure and supports near‑term R&D or commercialization steps.
Lean Operating Structure (small Headcount)A very small employee base (12) implies low fixed overhead and organizational nimbleness, which helps conserve cash and extend runway while management pursues partnerships or targeted commercialization, preserving resources for core platform development.
Bears Say
Small And Declining Revenue BaseA small revenue base (~$2.6M TTM) that is declining materially constrains the firm's ability to fund R&D, scale manufacturing, or attract large partners. Persistent revenue contraction undermines the commercial proof‑points needed to convert the platform into sustainable, recurring revenue streams.
Negative Gross Profit And Large Operating LossesNegative gross profit and outsized operating/net losses indicate the core unit economics are currently unprofitable. Until gross margins improve, the company will face structural profitability headwinds that continuously erode cash reserves and limit reinvestment into commercialization or scale.
Highly Stressed Balance Sheet; Negative EquityNegative shareholders' equity and meaningful debt versus a small asset base create sustained solvency and financing risk. This structural capital weakness limits strategic flexibility, increases the likelihood of dilutive capital raises or restructuring, and complicates long‑term partner confidence.
Rapid Dose Therapeutics Corp News
DOSE FAQ
What was Rapid Dose Therapeutics Corp’s price range in the past 12 months?
Rapid Dose Therapeutics Corp lowest stock price was C$0.08 and its highest was C$0.20 in the past 12 months.
What is Rapid Dose Therapeutics Corp’s market cap?
Rapid Dose Therapeutics Corp’s market cap is C$13.64M.
When is Rapid Dose Therapeutics Corp’s upcoming earnings report date?
Rapid Dose Therapeutics Corp’s upcoming earnings report date is Oct 22, 2026 which is in 70 days.
How were Rapid Dose Therapeutics Corp’s earnings last quarter?
Currently, no data Available
Is Rapid Dose Therapeutics Corp overvalued?
According to Wall Street analysts Rapid Dose Therapeutics Corp’s price is currently Overvalued.
Does Rapid Dose Therapeutics Corp pay dividends?
Rapid Dose Therapeutics Corp does not currently pay dividends.
What is Rapid Dose Therapeutics Corp’s EPS estimate?
Rapid Dose Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rapid Dose Therapeutics Corp have?
Rapid Dose Therapeutics Corp has 136,444,840 shares outstanding.
What happened to Rapid Dose Therapeutics Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rapid Dose Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:DOSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagship product is QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter medicines—directly into the bloodstream. They offer specific QuickStrip variants like QuickStrip energy for caffeine delivery, QuickStrip B12 for vitamin B12 supplementation, and QuickStrip sleep for melatonin. Beyond its proprietary products, the firm also delivers comprehensive services encompassing product innovation, manufacturing, and consultation to industries including nutraceuticals, cannabis healthcare, and pharmaceutical production. Rapid Dose Therapeutics maintains a significant research collaboration with McMaster University, focusing on crafting enhanced biopolymer compositions for oral dissolvable thin films and investigating an orally administered vaccine candidate for COVID-19.
Technical Analysis
BriaCell Therapeutics
―
Hemostemix
―
Britannia Life Sciences Inc
―
―
Telescope Innovations Corp
―